Kukje Pharma Co., Ltd. (002720.KS)
KRW 4970.0
(-2.17%)
KRW 4970.0
(-2.17%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -8.41 Billion KRW | -336.56% |
| 2022 | 3.55 Billion KRW | 328.65% |
| 2021 | -1.55 Billion KRW | -170.62% |
| 2020 | 2.2 Billion KRW | 146.26% |
| 2019 | -4.76 Billion KRW | -317.17% |
| 2018 | 2.19 Billion KRW | 100.74% |
| 2017 | 1.09 Billion KRW | 41.29% |
| 2016 | 773.06 Million KRW | 113.01% |
| 2015 | -5.94 Billion KRW | 14.27% |
| 2014 | -6.93 Billion KRW | -426.19% |
| 2013 | 2.12 Billion KRW | 111.22% |
| 2012 | -18.94 Billion KRW | -2141.38% |
| 2011 | 927.8 Million KRW | -78.49% |
| 2010 | 4.31 Billion KRW | -37.11% |
| 2009 | 6.85 Billion KRW | 3.86% |
| 2008 | 6.6 Billion KRW | 6.1% |
| 2007 | 6.22 Billion KRW | 1.32% |
| 2006 | 6.14 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 2.74 Billion KRW | 806.42% |
| 2024 Q2 | 597.39 Million KRW | -78.27% |
| 2023 Q1 | 833.3 Million KRW | 167.41% |
| 2023 Q4 | -389.14 Million KRW | 85.0% |
| 2023 FY | -8.41 Billion KRW | -336.56% |
| 2023 Q3 | -2.59 Billion KRW | 58.6% |
| 2023 Q2 | -6.26 Billion KRW | -851.89% |
| 2022 FY | 3.55 Billion KRW | 328.65% |
| 2022 Q1 | 2.14 Billion KRW | 164.18% |
| 2022 Q4 | -1.23 Billion KRW | -184.86% |
| 2022 Q2 | 1.18 Billion KRW | -44.7% |
| 2022 Q3 | 1.45 Billion KRW | 22.71% |
| 2021 Q1 | 852.5 Million KRW | 123.24% |
| 2021 Q2 | 126.59 Million KRW | -85.15% |
| 2021 Q3 | 806.26 Million KRW | 536.9% |
| 2021 Q4 | -3.34 Billion KRW | -514.81% |
| 2021 FY | -1.55 Billion KRW | -170.62% |
| 2020 Q3 | 669.38 Million KRW | 123.18% |
| 2020 Q2 | 299.93 Million KRW | -93.88% |
| 2020 FY | 2.2 Billion KRW | 146.26% |
| 2020 Q1 | 4.9 Billion KRW | 1028.34% |
| 2020 Q4 | -3.66 Billion KRW | -647.91% |
| 2019 Q3 | 835.49 Million KRW | 111.77% |
| 2019 FY | -4.76 Billion KRW | -317.17% |
| 2019 Q1 | 2.02 Billion KRW | 427.51% |
| 2019 Q2 | -7.09 Billion KRW | -449.9% |
| 2019 Q4 | -527.96 Million KRW | -163.19% |
| 2018 FY | 2.19 Billion KRW | 100.74% |
| 2018 Q4 | 384.48 Million KRW | -69.53% |
| 2018 Q3 | 1.26 Billion KRW | 385.47% |
| 2018 Q2 | -442.04 Million KRW | -144.73% |
| 2018 Q1 | 988.3 Million KRW | 237.99% |
| 2017 Q4 | -716.19 Million KRW | -182.71% |
| 2017 Q1 | 741.02 Million KRW | 94.64% |
| 2017 FY | 1.09 Billion KRW | 41.29% |
| 2017 Q2 | 201.47 Million KRW | -72.81% |
| 2017 Q3 | 865.94 Million KRW | 329.79% |
| 2016 Q4 | 380.7 Million KRW | 301.23% |
| 2016 Q1 | 657.95 Million KRW | 109.2% |
| 2016 Q2 | -76.41 Million KRW | -111.61% |
| 2016 Q3 | -189.19 Million KRW | -147.6% |
| 2016 FY | 773.06 Million KRW | 113.01% |
| 2015 Q3 | -737.97 Million KRW | -157.82% |
| 2015 Q4 | -7.14 Billion KRW | -868.67% |
| 2015 FY | -5.94 Billion KRW | 14.27% |
| 2015 Q1 | 667.17 Million KRW | 109.11% |
| 2015 Q2 | 1.27 Billion KRW | 91.31% |
| 2014 Q1 | -865.72 Million KRW | -139.3% |
| 2014 Q4 | -7.32 Billion KRW | -711.79% |
| 2014 Q3 | 1.19 Billion KRW | 1919.5% |
| 2014 Q2 | 59.26 Million KRW | 106.85% |
| 2014 FY | -6.93 Billion KRW | -426.19% |
| 2013 Q1 | 350.82 Million KRW | 104.23% |
| 2013 FY | 2.12 Billion KRW | 111.22% |
| 2013 Q3 | -987.52 Million KRW | -276.66% |
| 2013 Q4 | 2.2 Billion KRW | 323.07% |
| 2013 Q2 | 559 Million KRW | 59.34% |
| 2012 Q4 | -8.28 Billion KRW | -717.69% |
| 2012 FY | -18.94 Billion KRW | -2141.38% |
| 2012 Q2 | -7.34 Billion KRW | -219.17% |
| 2012 Q3 | -1.01 Billion KRW | 86.21% |
| 2012 Q1 | -2.3 Billion KRW | 0.0% |
| 2011 Q3 | 156.9 Million KRW | -26.29% |
| 2011 Q1 | 2.66 Billion KRW | 580.31% |
| 2011 Q2 | 212.86 Million KRW | -92.0% |
| 2011 FY | 927.8 Million KRW | -78.49% |
| 2010 Q4 | 391.33 Million KRW | -47.57% |
| 2010 FY | 4.31 Billion KRW | -37.11% |
| 2010 Q1 | 656.24 Million KRW | -71.03% |
| 2010 Q2 | 513.43 Million KRW | -21.76% |
| 2010 Q3 | 746.47 Million KRW | 45.39% |
| 2009 Q2 | 1.33 Billion KRW | 101.16% |
| 2009 Q3 | 2.6 Billion KRW | 94.96% |
| 2009 Q4 | 2.26 Billion KRW | -12.96% |
| 2009 FY | 6.85 Billion KRW | 3.86% |
| 2009 Q1 | 663.62 Million KRW | -72.83% |
| 2008 Q3 | 1.17 Billion KRW | -49.4% |
| 2008 FY | 6.6 Billion KRW | 6.1% |
| 2008 Q2 | 2.32 Billion KRW | 114.08% |
| 2008 Q4 | 2.44 Billion KRW | 107.81% |
| 2008 Q1 | 1.08 Billion KRW | -20.13% |
| 2007 Q3 | 1.83 Billion KRW | -5.4% |
| 2007 FY | 6.22 Billion KRW | 1.32% |
| 2007 Q2 | 1.93 Billion KRW | 0.0% |
| 2007 Q4 | 1.35 Billion KRW | -25.8% |
| 2006 FY | 6.14 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -17.188% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 114.512% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 85.877% |
| HANDOK Inc. | -28.79 Billion KRW | 70.778% |
| Yuhan Corporation | 93.5 Billion KRW | 108.999% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 175.659% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 66.084% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 105.755% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 339.844% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -235.746% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | -305.764% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | -85.978% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 137.681% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -17.188% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 59.815% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 334.84% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 92.885% |
| JW Holdings Corporation | 19.02 Billion KRW | 144.229% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 89.338% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 103.96% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 122.74% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 85.32% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 237.464% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 605.86% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 268.144% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -17.188% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 122.765% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 107.547% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 122.74% |
| Yuhan Corporation | 93.5 Billion KRW | 108.999% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 48.213% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | -117.136% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 237.52% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 122.74% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 144.511% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 117.437% |
| CKD Bio Corp. | -24.19 Billion KRW | 65.216% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 135.185% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 130.67% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 128.263% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 85.32% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 117.902% |
| Boryung Corporation | 40.2 Billion KRW | 120.932% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 73.14% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -235.746% |
| JW Lifescience Corporation | 28.14 Billion KRW | 129.901% |